JP2022540611A5 - - Google Patents
Info
- Publication number
- JP2022540611A5 JP2022540611A5 JP2022501134A JP2022501134A JP2022540611A5 JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5 JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061352A JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872915P | 2019-07-11 | 2019-07-11 | |
| US62/872,915 | 2019-07-11 | ||
| PCT/US2020/041282 WO2021007371A1 (en) | 2019-07-11 | 2020-07-08 | Dll3-targeting antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Division JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540611A JP2022540611A (ja) | 2022-09-16 |
| JP2022540611A5 true JP2022540611A5 (enExample) | 2023-07-12 |
| JP7661299B2 JP7661299B2 (ja) | 2025-04-14 |
Family
ID=74115317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501134A Active JP7661299B2 (ja) | 2019-07-11 | 2020-07-08 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12441789B2 (enExample) |
| EP (1) | EP3997127A4 (enExample) |
| JP (2) | JP7661299B2 (enExample) |
| KR (1) | KR20220034167A (enExample) |
| CN (3) | CN119080930A (enExample) |
| AU (1) | AU2020310894A1 (enExample) |
| BR (1) | BR112022000216A2 (enExample) |
| CA (1) | CA3146566A1 (enExample) |
| CO (1) | CO2022001195A2 (enExample) |
| IL (1) | IL289585A (enExample) |
| MX (1) | MX2022000325A (enExample) |
| PH (1) | PH12022550056A1 (enExample) |
| WO (1) | WO2021007371A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718257T3 (enExample) * | 2014-05-30 | 2018-04-14 | ||
| BR112022000216A2 (pt) * | 2019-07-11 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a dll3 e usos dos mesmos |
| WO2022153195A1 (en) * | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| WO2022153194A1 (en) * | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2022237647A1 (zh) * | 2021-05-08 | 2022-11-17 | 上海齐鲁制药研究中心有限公司 | 针对dll3的结合分子及其应用 |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| WO2023034555A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| EP4396224A4 (en) * | 2021-09-02 | 2025-11-12 | Memorial Sloan Kettering Cancer Center | Anti-DLL3 Antibodies and Their Uses |
| EP4454662A4 (en) * | 2021-12-23 | 2025-04-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY |
| KR20240149438A (ko) | 2022-02-27 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Cd277 및 종양-항원에 대한 이중특이적 항체 |
| CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288253B2 (en) | 2003-08-08 | 2007-10-30 | Amgen Fremont, Inc. | Antibodies directed to parathyroid hormone (PTH) and uses thereof |
| AU2007325872B2 (en) * | 2006-11-08 | 2012-12-13 | Macrogenics West, Inc. | TES7 and antibodies that bind thereto |
| EP3907242A1 (en) | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| WO2012013813A1 (en) | 2010-07-30 | 2012-02-02 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| AU2013215254B2 (en) * | 2012-01-31 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| RU2014138474A (ru) * | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| WO2015127407A1 (en) * | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| EP3221356B1 (en) | 2014-11-20 | 2020-09-02 | F.Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules against folr1 and cd3 |
| BR112022000216A2 (pt) * | 2019-07-11 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a dll3 e usos dos mesmos |
-
2020
- 2020-07-08 BR BR112022000216A patent/BR112022000216A2/pt unknown
- 2020-07-08 JP JP2022501134A patent/JP7661299B2/ja active Active
- 2020-07-08 AU AU2020310894A patent/AU2020310894A1/en active Pending
- 2020-07-08 CA CA3146566A patent/CA3146566A1/en active Pending
- 2020-07-08 EP EP20836805.0A patent/EP3997127A4/en active Pending
- 2020-07-08 CN CN202411174923.9A patent/CN119080930A/zh active Pending
- 2020-07-08 KR KR1020227004114A patent/KR20220034167A/ko active Pending
- 2020-07-08 US US17/622,404 patent/US12441789B2/en active Active
- 2020-07-08 PH PH1/2022/550056A patent/PH12022550056A1/en unknown
- 2020-07-08 MX MX2022000325A patent/MX2022000325A/es unknown
- 2020-07-08 WO PCT/US2020/041282 patent/WO2021007371A1/en not_active Ceased
- 2020-07-08 CN CN202080062231.9A patent/CN114341182B/zh active Active
- 2020-07-08 CN CN202411174926.2A patent/CN118955717A/zh active Pending
-
2022
- 2022-01-03 IL IL289585A patent/IL289585A/en unknown
- 2022-02-04 CO CONC2022/0001195A patent/CO2022001195A2/es unknown
-
2025
- 2025-04-02 JP JP2025061352A patent/JP2025156278A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7235256B2 (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| CN105579471B (zh) | 结合人程序性死亡配体1(pd-l1)的抗体 | |
| JP2009100745A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP7624497B2 (ja) | ヒトｐｄ－ｌ２抗体およびその使用方法 | |
| JP2005518789A5 (enExample) | ||
| JP7713995B2 (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法 | |
| US12325747B2 (en) | Human PD-L1 antibodies and methods of use therefor | |
| JP2024506315A5 (enExample) | ||
| JP2022538117A5 (enExample) | ||
| US20250129167A1 (en) | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor | |
| JP2024540148A5 (enExample) | ||
| CN112979795A (zh) | 抗体组合产品及其在新冠肺炎检测中应用 | |
| JP2023537002A5 (enExample) | ||
| RU2021139258A (ru) | Dll3-нацеливающие антитела и их применения | |
| CN118240079A (zh) | 抗脂联素抗体、检测脂联素的试剂和试剂盒 | |
| CN120424221B (zh) | 靶向德曲妥珠单抗的抗体及其用途 | |
| TW201915016A (zh) | 單株抗體或其抗原結合片段及其用途 | |
| JP2025512888A (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体ならびにその使用方法 | |
| CN121975014A (zh) | 抗dll3的抗体及其相关产品和应用 | |
| KR20250064725A (ko) | 사스 코로나바이러스 2 중화를 위한 이뮤노글로불린 a 항체 및 이의 용도 | |
| JP2024531913A5 (enExample) |